Immune Responses to Zoster Vaccines

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2019 Jan 25

PMID 30676834

Citations 19

Authors

Myron J Levin

Adriana Weinberg

Affiliations

Soon will be listed here.

Abstract

There are two licensed herpes zoster vaccines. One is a live vaccine (ZVL) based on an attenuated varicella-zoster virus (VZV). The other is a recombinant vaccine (RZV) based on the VZV glycoprotein E (gE) combined with AS01B, a multicomponent adjuvant system. RZV is superior to ZVL in efficacy, and differs from ZVL in that protection is not diminished by the age of the vaccinee and has not waned significantly during 4 years of follow-up. Immunologic studies demonstrated higher peak memory and persistence of T cell responses in RZV compared with ZVL recipients. RZV recipients also showed development and persistence of polyfunctional T cell responses. Taken together, we conclude that the immunologic data parallel and support the higher efficacy over time of RZV compared with ZVL.

Citing Articles

A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates.

Li Y, Tian S, Ai Y, Hu Z, Ma C, Fu M Front Immunol. 2024; 15:1419634.

PMID: 39081325 PMC: 11286566. DOI: 10.3389/fimmu.2024.1419634.

Current development of therapeutic vaccines for the treatment of chronic infectious diseases.

Park P, Fatima M, An T, Moon Y, Woo S, Youn H Clin Exp Vaccine Res. 2024; 13(1):21-27.

PMID: 38362373 PMC: 10864879. DOI: 10.7774/cevr.2024.13.1.21.

Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques.

Huang L, Zhao T, Zhao W, Shao A, Zhao H, Ma W Emerg Microbes Infect. 2024; 13(1):2309985.

PMID: 38258878 PMC: 10860463. DOI: 10.1080/22221751.2024.2309985.

Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate.

Petherbridge L, Davis C, Robinson A, Evans T, Sebastian S Vaccines (Basel). 2023; 11(11).

PMID: 38006010 PMC: 10674764. DOI: 10.3390/vaccines11111679.

Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors.

Kallmark H, Bergstrom T, Nagel J, Gullstrand B, Einarsson J, Bengtsson A Rheumatology (Oxford). 2023; 63(7):2024-2033.

PMID: 37851412 PMC: 11215978. DOI: 10.1093/rheumatology/kead552.

References

Wilson A, Sharp M, Koropchak C, Ting S, Arvin A . Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis. 1992; 165(1):119-26. DOI: 10.1093/infdis/165.1.119. View

Kawai K, Gebremeskel B, Acosta C . Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014; 4(6):e004833. PMC: 4067812. DOI: 10.1136/bmjopen-2014-004833. View

Hata A, Asanuma H, Rinki M, Sharp M, Wong R, Blume K . Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002; 347(1):26-34. DOI: 10.1056/NEJMoa013441. View

Coccia M, Collignon C, Herve C, Chalon A, Welsby I, Detienne S . Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines. 2017; 2:25. PMC: 5627273. DOI: 10.1038/s41541-017-0027-3. View

Qi Q, Cavanagh M, Le Saux S, Namkoong H, Kim C, Turgano E . Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med. 2016; 8(332):332ra46. PMC: 4878824. DOI: 10.1126/scitranslmed.aaf1725. View

Levin M, Kroehl M, Johnson M, Hammes A, Reinhold D, Lang N . Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018; 128(10):4429-4440. PMC: 6159998. DOI: 10.1172/JCI121484. View

Cunningham A, Levin M . Herpes Zoster Vaccines. J Infect Dis. 2018; 218(suppl_2):S127-S133. DOI: 10.1093/infdis/jiy382. View

Gershon A, Gershon M . Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013; 26(4):728-43. PMC: 3811230. DOI: 10.1128/CMR.00052-13. View

Mitchell B, Bloom D, Cohrs R, Gilden D, Kennedy P . Herpes simplex virus-1 and varicella-zoster virus latency in ganglia. J Neurovirol. 2003; 9(2):194-204. DOI: 10.1080/13550280390194000. View

10.

Lelic A, Verschoor C, Lau V, Parsons R, Evelegh C, Bowdish D . Immunogenicity of Varicella Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents. J Infect Dis. 2016; 214(12):1905-1910. DOI: 10.1093/infdis/jiw462. View

11.

Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek J, Richardus J . Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014; 32(15):1745-53. DOI: 10.1016/j.vaccine.2014.01.019. View

12.

Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus J, Plassmann G . Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2015; 34(6):863-8. DOI: 10.1016/j.vaccine.2015.09.073. View

13.

Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E . Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. Am J Epidemiol. 2018; 187(1):161-169. PMC: 6018833. DOI: 10.1093/aje/kwx245. View

14.

Cunningham A, Lal H, Kovac M, Chlibek R, Hwang S, Diez-Domingo J . Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016; 375(11):1019-32. DOI: 10.1056/NEJMoa1603800. View

15.

Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini S . Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012; 30(20):3126-35. DOI: 10.1016/j.vaccine.2012.01.088. View

16.

Yawn B, Saddier P, Wollan P, St Sauver J, Kurland M, Sy L . A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007; 82(11):1341-9. DOI: 10.4065/82.11.1341. View

17.

Weinberg A, Lazar A, Zerbe G, Hayward A, Chan I, Vessey R . Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis. 2010; 201(7):1024-30. PMC: 3136368. DOI: 10.1086/651199. View

18.

Schunemann S, Mainka C, Wolff M . Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals. Intervirology. 1998; 41(2-3):98-102. DOI: 10.1159/000024920. View

19.

Redman R, Nader S, Zerboni L, Liu C, Wong R, BROWN B . Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997; 176(3):578-85. DOI: 10.1086/514077. View

20.

Cinque P, Bossolasco S, Vago L, Fornara C, Lipari S, Racca S . Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection?. Clin Infect Dis. 1997; 25(3):634-9. DOI: 10.1086/513754. View